Verona says sec­ond PhI­II for COPD drug hits the mark, plans 2023 NDA fil­ing

UK-based biotech Verona Phar­ma said Tues­day morn­ing that its drug, en­sifen­trine, passed its sec­ond late-stage tri­al for the com­mon lung dis­ease COPD.

In Au­gust, Verona …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER